Myelodysplastic syndromes: moving towards personalized management

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Myelodysplastic syndromes (MDS) originate from hematopoietic stem cells but exhibit significant biological and genetic heterogeneity.
• Clinical manifestations include cytopenia and a considerable risk of transformation into acute myeloid leukemia.
• WHO classification defines MDS by cytopenia, bone marrow dysplasia, and specific karyotypic abnormalities.

Purpose of the Study:

• To provide a comprehensive overview of the current clinical evaluation, biology, and therapeutic interventions for myelodysplastic syndromes.
• To highlight advancements in understanding MDS pathogenesis through next-generation sequencing and integrated diagnostics.
• To discuss the evolving landscape of MDS treatment, including novel therapies and stem cell transplantation.

Main Methods:

• Review of current literature on MDS pathogenesis, classification, and treatment.
• Integration of morphological, cytogenetic, and molecular genetic data.
• Analysis of clinical trial data for novel therapeutic agents and stem cell transplantation outcomes.

Main Results:

• Next-generation sequencing has significantly advanced the understanding of MDS pathogenesis.
• Treatment strategies for higher-risk MDS primarily involve hypomethylating agents, with novel combinations under investigation.
• Erythropoiesis-stimulating agents are first-line for lower-risk MDS anemia, with luspatercept and lenalidomide showing efficacy in specific subtypes.
• Hematopoietic stem cell transplantation offers curative potential with improving safety and efficacy.

Conclusions:

• Precision medicine for MDS is still developing, with a need for novel therapeutics to improve patient outcomes.
• Integrated diagnostic approaches are crucial for improved classification and prognostication of MDS.
• Advances in stem cell transplantation are enhancing cure rates and reducing treatment-related toxicity in MDS.